Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

European Journal of Haematology

Volumn 86, Issue 2, 2011, Pages 124-128

  Riihijärvi, Sari ^a,b   Taskinen, Minna ^a,b   Jerkeman, Mats ^c   Leppä, Sirpa ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

B cell non Hodgkin lymphoma; Gender; Immunochemotherapy; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 78651465901     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01541.x     Document Type: Article

References (12)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
2. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7.
3. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92.
4. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23.
6. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.
7. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
8. IPI-Project. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
9. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
10. Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008;49:462-9.
11. Pfreundschuh M, Murawski N, Zeynalova S, et al. Male sex is associated with lower rituximab trough serum levels and evolves as a significant prognostic factor in elderly patients with DLBCL treated with R-CHOP: results from 4 prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL). Blood 2009;114:3715a.
12. Cho HJ, Eom HS, Kim HJ, Kim IS, Lee GW, Kong SY. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2010;198:40-6.